Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Algorithm Developed to Predict How and When Proteins Behave Badly

By LabMedica International staff writers
Posted on 05 Mar 2012
Scientists have developed an algorithm that can predict which regions of a protein are susceptible to exposure upon misfolding, and how mutations in the protein and alterations in the cellular environment might affect the stability of these vulnerable regions. More...


The predictions help scientists gain a better determination of protein mechanisms, and may one day help in developing treatments to fight currently lethal neurodegenerative diseases effectively.

Several neurodegenerative diseases--including Alzheimer’s and amyotrophic lateral sclerosis (ALS), recruit and transform healthy proteins to the misfolded form, and amass in large clumps that glue up the processes of the nervous system.

The investigators presented their findings at the 56th annual meeting of the Biophysical Society (BPS), held February 25-29, 2012, in San Diego, CA, USA. The algorithm developed by the researchers utilizes the energy equations of thermodynamics to calculate the likelihood that certain stretches of protein will be displayed when the protein misfolds. Since the exposed regions are specific to the misfolded version of the protein, researchers can use these areas as targets for diagnostic and therapeutic treatments. The algorithm can be modified for different proteins, and it predicts several potential target regions for each protein. The investigators have used it to study neurodegenerative disease-causing proteins as well as misfolded proteins that have been implicated in some cancers.

More recently, the researchers used computer simulations to manipulate proteins in a virtual environment, assessing out how simple it is for mutated proteins to misfold and propagate. Using this application has helped the team predict the progression of hereditary ALS disease. “The fact that we can predict the lifetime of an individual diagnosed with hereditary ALS from simulations of a protein’s mechanical properties is something that is both satisfying and that gives one pause,” said Dr. Steven Plotkin, a biophysicist at the University of British Columbia (Vancouver, Canada) who studies the process of protein misfolding. “We hope that such information might give some clues as to how to develop effective therapies for this disease.”

Related Links:
University of British Columbia
Biophysical Society Annual Meeting


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.